Novo Nordisk takes out the ax and aims at R&D, chopping 1,000 jobs
The diabetes market is a tough, competitive field dominated by a few major players. And today one of the most prominent in the bunch, Novo …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
